Boundless Bio, INC Form 4 insider transactions

Kevin Tang and 1 other reported changes in beneficial ownership of Boundless Bio, Inc. common stock on July 17, 2026.

Kevin Tang and 1 other reported changes in beneficial ownership of Boundless Bio, Inc. common stock on July 14, 2026.

Kevin Tang and 1 other reported changes in beneficial ownership of Boundless Bio, Inc. common stock on July 9, 2026.

Kevin Tang, a director and 10% owner of Boundless Bio, Inc., has acquired a significant number of common shares through various transactions in early July 2026.

Several directors and 10% owners of Boundless Bio, Inc. have reported transactions involving common stock and stock options.

ARCH Venture Funds report changes in beneficial ownership of Boundless Bio, Inc. common stock, including option exercises and share dispositions.

Director Kevin Tang acquired a significant number of Boundless Bio common shares through multiple transactions in late June and early July 2026.

Kevin Tang, a director and 10% owner of Boundless Bio, Inc., reported multiple transactions involving the acquisition of common stock.

Boundless Bio, Inc. director Nancy Whiting was granted 32,000 stock options as part of her compensation package.

Boundless Bio, Inc. director Jonathan E. Lim was granted 48,000 stock options as part of his compensation package.

Director James Christensen was granted 32,000 stock options in Boundless Bio, Inc. as part of standard compensation.

Director Jennifer Lew was granted 32,000 stock options in Boundless Bio, Inc. as part of a standard equity compensation arrangement.

Boundless Bio's Chief Legal Officer, Jessica Oien, was granted 220,000 stock options with an exercise price of $1.26, vesting over 48 months.

Boundless Bio's Chief Scientific Officer, Christian Hassig, was granted 230,000 stock options with an exercise price of $1.26, vesting over 48 months.

Boundless Bio's Chief Medical Officer, Robert Doebele, was granted 230,000 stock options with a vesting schedule over 48 months.

Boundless Bio, Inc. CEO Zachary Hornby acquired 600,000 stock options with an exercise price of $1.26, vesting over 48 months.

Boundless Bio, Inc. granted 140,000 stock options to Senior VP, Finance, Controller and Treasurer David A. Hinkle with an exercise price of $1.26.

Boundless Bio, Inc. director Christine Brennan was granted 16,000 stock options with an exercise price of $1.03, vesting over 12 months.

Boundless Bio, Inc. Director James Christensen was granted 16,000 stock options with an exercise price of $1.03, vesting over 12 months.

Boundless Bio, Inc. Director Jennifer Lew was granted 16,000 stock options with an exercise price of $1.03, aligning her interests with the company's long-term performance.

Jonathan E. Lim, a Director at Boundless Bio, Inc., was granted 24,000 stock options with an exercise price of $1.03, vesting over 12 months contingent on continued service.

Kristina Burow, a Director and 10% Owner of Boundless Bio, Inc., was granted 16,000 stock options with an exercise price of $1.03, vesting over 12 months starting June 23, 2025.

Boundless Bio, Inc. Director Nancy Whiting was granted 16,000 stock options with an exercise price of $1.03, vesting over 12 months.

Robert Doebele, Chief Medical Officer of Boundless Bio, acquired 180,000 stock options on February 3, 2025, according to a recent SEC filing.

David Hinkle, SVP of Finance and Controller at Boundless Bio, reports the acquisition of stock options.

Christian Hassig, Chief Scientific Officer of Boundless Bio, Inc., acquired 95,000 stock options on January 22, 2025, vesting monthly starting February 1, 2025.

Zachary Hornby, President & CEO of Boundless Bio, Inc., reports the acquisition of 295,000 stock options on January 22, 2025.

Jessica Oien, Chief Legal Officer and Corporate Secretary of Boundless Bio, Inc., acquired 90,000 stock options on January 22, 2025, vesting monthly starting February 1, 2025.

Christian Hassig, Chief Scientific Officer of Boundless Bio, reports the repricing of stock options on August 19, 2024, according to a Form 4 filing with the SEC.

Jessica Oien, Chief Legal Officer and Corporate Secretary of Boundless Bio, Inc., repriced several stock option grants on August 19, 2024.